Delivering extraordinary. Empowering ordinary.

We’re developing novel oral medicines for rare diseases to help patients take part in the everyday activities they enjoy.

Learn More

Structure-guided Drug Design

We combine traditional cell biology with medicinal chemistry to build synthetic compounds that bind to specific protein targets to fight disease.

See Our Science

We are developing a pipeline of oral drugs for rare diseases, including our next generation kallikrein inhibitor for hereditary angioedema (HAE).

View Our Pipeline

Stay up to date with the latest discoveries, events, and reports from BioCryst.

April 2, 2020: BioCryst Appoints Anthony Doyle Chief Financial Officer
March 30, 2020: European Medicines Agency Validates Marketing Authorization Application for Oral, Once-Daily Berotralstat (BCX7353) to Prevent HAE Attacks
March 16, 2020: Berotralstat (BCX7353) Significantly Reduced Use of Acute On-Demand Medicine in HAE Patients in APeX-2

VIEW ALL PRESS RELEASES

We are a collection of passionate individuals united by a commitment to scientific excellence and an unwavering focus on the needs of patients.

JOB OPENINGS